GSK Share Price Today: Stock Slips as Buyback Rolls On, Arexvy in Focus
GSK shares slipped 0.5% to 2,015 pence in London Tuesday after the company disclosed buying 628,000 shares on March 16 under its £2 billion buyback plan. Total repurchases since February 17 reached 10.55 million shares. The current tranche, worth up to £450 million, runs until April 24. Investors are also watching the expanded U.S. approval for GSK’s RSV vaccine Arexvy.